| IPSEN S.A. PORT. EO 1 |
| Frankreich |
| Gesundheit |
| FR0010259150 / A0ESMG |
| I7G (Frankfurt) |
| FRA:I7G, ETR:I7G, I7G:GR |
| - |
| https://www.ipsen.com/ |
|
Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929..
>Volltext.. |
| 13001.98 Mio. EUR |
| 11995.28 Mio. EUR |
| 4009.84 Mio. EUR |
| 1921.82 Mio. EUR |
| 507.98 Mio. EUR |
| 6.14 EUR |
| 954.52 Mio. EUR |
| 1952.55 Mio. EUR |
| 1293.04 Mio. EUR |
| 1.14 |
| 13.63% |
| 14.45% |
| 1.6 EUR |
| 1.02% |
| 0.96% |
| 03.06.26 - 1.6€ 04.06.25 - 1.4€ >weitere anzeigen... |
| - |
| IPSEN |
| 02.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|